Immix reports 89% complete response rate in NEXICART-2, plans mid-2027 BLANov 12Quarterly updateImmix Biopharma, Inc.
PTC Therapeutics reports Q2 2026 revenue of $361 million, raises full-year guidanceJul 30Quarterly updatePTC Therapeuticssepiapterin